U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Frontida BioPharm Inc - 04/28/2017
  1. Warning Letters

CLOSEOUT LETTER

Frontida BioPharm Inc

Recipient:
Frontida BioPharm Inc

United States

Issuing Office:

United States

 

  

Black HHS-Blue FDA Logo

 

 

 
Philadelphia District
900 U.S. Custom House
2nd and Chestnut Street
Philadelphia, PA 19106
Telephone: (215) 597-4390

CERTIFIED MAIL
RETURN RECEIPT REQUESTED

April 28, 2017

Ronald H. Connolly, Chief Operation Officer
Frontida BioPharm Inc.
1100 Orthodox Street
Philadelphia, PA 19124

Dear Mr. Connollly:

The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter 16-PHI-10, dated August 15, 2016. Based on our evaluation, it appears that you have addressed the violation(s) contained in the Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or you firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and it implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Yvette Johnson
Compliance Officer
Philadelphia District Office 

Back to Top